Message #7 From:
Stock News Bot Date: October 17, 2006 04:00:00 AM
PKTX News ProtoKinetix, Inc. Publishes Letter: Anti-Aging Glycoprotein AAGP(TM) Protects and Repairs
VANCOUVER, British Columbia--(BUSINESS WIRE)--ProtoKinetix, Inc. (OTCBB:PKTX) is publishing a letter from the
lead scientists of ITTEC Stem, Inc. regarding their observations of
additional properties of AAGP™. This letter
reads as follows:
“A number of studies have clearly demonstrated
the UV protective capacity of anti-aging glycoprotein AAGP. Indeed,
under intense UV light exposures a survival advantage of between 20-40%
has been repeatedly demonstrated in cell lines incubated with AAGP while
being simultaneously exposed to UV light. Interestingly, the latest
exposure experiments suggest that AAGP may not only be protecting cells
from UV light but may also be acting at a molecular level to possibly
induce repair of damaged cells.
“Some of the most recent data includes 1)
cell lines exposed to UV light in the presence of AAGP but with AAGP removed
immediately following UV exposure and 2) cell lines exposed to UV
light with AAGP only added after
the UV exposure. In both situations, the cells incubated with AAGP had a
survival advantage similar as if AAGP had been added throughout and
after the UV exposures. In addition to these results, an additional set
of experiments demonstrated how even after 8 days following UV exposure
and without changing the media throughout those 8 days, the only cells
that were still viable were those that had been exposed to AAGP at one
time point or another. Note that not changing the media in this
experiment was done purposely so as to maintain a consistent environment
resembling significant cell death and acidosis. The fact that cells
survived in the AAGP treated cells (even when treated only after UV
exposure) and that viability was maintained even after the harsh
cellular conditions suggests AAGP may be acting at the molecular level
(as a signalling molecule) to protect and potentially repair cells or
promote their survival. The therapeutic benefits of such a
protection/repair mechanism could potentially be of marked use in cases
of myocardial infarction and stroke amongst other pathologies.”
- Sammer Hussein and Michael Palumbo. ITTEC Stem, Inc.
About ProtoKinetix:
ProtoKinetix, Inc. is a Biotechnical Company dedicated to the
development of a family of synthetic antifreeze glycoproteins (AAGP™)
for human and veterinary medicine, the bio technology and cosmetic
industries. Using previously published research on native antifreeze
proteins and antifreeze glycoproteins as a guide, and coordinating a
vast pool of world recognized intellectual talent in a networked
environment, PKTX is conducting rapid and meaningful research with a
view to developing markets for this very useful family of molecules.
Sign up for free automatic email news alerts at our new website at: www.protokinetix.com
The Private Securities Litigation Reform Act of 1995 provides a “safe
harbor” for forward-looking statements. Some
information included in this press release contains statements that are
forward-looking. Such forward-looking information involves significant
risks and uncertainties that could affect anticipated results in the
future and, accordingly, these results may differ materially from those
expressed in any forward-looking statements made by or on behalf of the
Company. For a description of additional risks and uncertainties, please
refer to the Company’s filings with the
Securities and Exchange Commission.
On behalf of the Board of Directors
Dr. John Todd –President
Company Office:
Suite # 1500
885 West Georgia Street
Vancouver, BC V6C 3E8
